Director, Launch Preparedness, Policy & Advocacy Strategy, and Execution Lead, non-MD

Director, Launch Preparedness, Policy & Advocacy Strategy, and Execution Lead, non-MD

• United States
  - New York
  - New York City

We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. To fully realize Pfizer’s purpose – Breakthroughs that change patients’ lives – we have established a clear set of expectations regarding “what” we need to achieve for patients and “how” we will go about achieving those goals.

The Launch Preparedness, Policy & Advocacy Strategy, and Execution Lead is a leadership role within the U.S. Vaccines Field Medical organization, accountable for launch preparedness, policy integration, advocacy strategy, and field medical readiness across priority vaccine and drug assets. The role operates at individual contributor level, with an initial focus on the Lyme Vaccine (LB6V) and responsibility to support additional vaccine and drug launches as portfolio priorities evolve.

• Set and govern national launch preparedness strategy and operating standards for priority U.S. vaccine and drug launches, with an initial focus on the Lyme Vaccine (LB6V) and flexibility to support additional assets as portfolio priorities evolve.
• Define, maintain, and govern enterprise‑wide launch readiness standards, success metrics, and policy‑related readiness expectations for Vaccines Field Medical, ensuring consistent application across assets and field teams.
• Serve as the escalation authority for policy‑driven risks and access barriers that may impact launch timing, uptake, or sustainability, providing strategic recommendations and decision support to U.S. Medical Affairs and Commercial leadership.
• Partner with HQ Brand Medical leads and cross‑functional stakeholders, including Commercial, Operations, Medical Analytics, and Vaccines Field Medical leadership, to anticipate and shape national field deployment models, engagement priorities, and enablement strategies, without duplicating asset‑level strategy ownership.
• Provide enterprise oversight and strategic direction for Pre‑Approval Information Exchange (PIE) readiness and execution, ensuring consistent governance, insight synthesis, and readiness expectations across launches.
• Leverage enterprise‑level medical insights, analytics, and engagement data to continuously refine launch preparedness frameworks and optimize field medical effectiveness at scale.
• Provide strategic oversight and direction for the development and deployment of launch‑related training, playbooks, and field readiness materials, ensuring alignment with enterprise standards and policy‑informed engagement expectations.
• Ensure scalable, repeatable, and policy‑integrated launch preparedness approaches are applied across pipeline and in‑line assets, rather than asset‑specific or ad hoc execution models.

• Serve as the Field Medical Policy Lead for U.S. Vaccines, with enterprise accountability for how field medical policy and advocacy engagement is operationalized, in close alignment with, but distinct from, the U.S. Medical Affairs Vaccines Policy team, which retains ownership of policy development.
• Set national strategic direction for field medical policy and advocacy engagement models that support launch readiness, lifecycle management, and access outcomes across the Vaccines portfolio.
• Provide enterprise‑level oversight and guidance for field medical engagement with key medical societies that influence vaccine recommendations, clinical guidelines, and access, ensuring consistent national standards rather than individual asset approaches.
• Lead and shape enterprise field medical engagement across national organizations, including ACOG, AAP, IDSA, ACP, AAFP, and other relevant professional societies, governing engagement frameworks rather than executing all interactions directly.
• Apply deep expertise in ACIP processes, medical society governance, payer coverage dynamics, and state‑level regulatory environments to proactively identify policy‑driven risks and opportunities requiring enterprise coordination or escalation.
• Translate policy, guideline, and…